Alumis Inc. filed a Form 8-K on September 1, 2026, disclosing that it had issued a press release and hosted a webcast presenting topline results from its LUMUS Phase 2b clinical trial of envudeucitinib in Systemic Lupus Erythematosus.
Key Highlights
- Trial readout announced: Alumis issued a press release titled "Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)" on September 1, 2026.
- Webcast presentation filed: Slides presented at a webcast regarding the LUMUS Phase 2b topline results, dated September 1, 2026, were filed as Exhibit 99.2.
- NDA submission planned: According to the filing, the company plans to submit an NDA for envudeucitinib in the fourth quarter of 2026.
- Additional indications cited: The filing references the potential for prespecified subgroup analyses to inform future Phase 3 development in SLE, as well as potential development in cutaneous lupus erythematosus and Sjögren's disease.
- Pipeline asset noted: The filing also references development of A-005 for neuroinflammatory and neurodegenerative diseases, including Parkinson's Disease.
- Exchange listing: Alumis common stock trades on NASDAQ:ALMS on The Nasdaq Global Select Market.
Alumis Discloses LUMUS Phase 2b Results and Clinical Development Plans for Envudeucitinib
Alumis Inc., a Delaware-incorporated biopharmaceutical company headquartered in South San Francisco, California, filed a Current Report on Form 8-K under Item 8.01 (Other Events) on September 1, 2026. According to the filing, the company simultaneously issued a press release announcing topline results from the LUMUS Phase 2b trial of envudeucitinib in Systemic Lupus Erythematosus and presented related slides at a webcast held on the same date.
The press release and the webcast presentation were filed as Exhibit 99.1 and Exhibit 99.2, respectively, and incorporated by reference into the report. The filing notes that "the information contained in the presentation is summary information that is intended to be considered in the context of the more complete information included in the Company's filings with the Securities and Exchange Commission." The filing does not include the actual topline efficacy or safety data from the LUMUS trial within the body of the 8-K itself.
The filing contains forward-looking statements attributed to Alumis, including plans to submit an NDA for envudeucitinib in the fourth quarter of 2026, the potential for prespecified subgroup analyses to inform future Phase 3 development in SLE, and the potential to develop envudeucitinib in additional interferon-driven diseases. The company states these are forward-looking statements "subject to significant risks and uncertainties that could cause actual results to differ materially," and explicitly disclaims any obligation to update them except as required by law. The report was signed by Martin Babler, President and Chief Executive Officer.
What Was Disclosed
Alumis filed an 8-K on September 1, 2026, announcing topline results from its LUMUS Phase 2b trial of envudeucitinib in SLE, attaching a press release and webcast presentation as exhibits, and noting plans for an NDA submission in the fourth quarter of 2026.




Please wait processing your request...